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Multiple sclerosis (MS) is a chronic disease. Classical 
natural history studies have shown that more than 
50% of patients will develop severe disability after 
15–30 years.1–4 However, when considering inception 
cohorts of patients seen from their very first attack, 
the rates of disability accumulation seem to be milder. 
In this sense, the clinically isolated syndromes (CIS) 
cohort from the National Hospital for Neurology and 
Neurosurgery, Queen Square, showed that only 25% 
had reached an Expanded Disability Status Scale 
(EDSS) of 6.0 after 20 years of follow-up.5 Despite 
these figures, there is still a subgroup of MS patients 
with an aggressive disease who develop severe 
disability early in the disease course. Although there 
is no established definition of aggressive MS, the 
early identification of this population would be of 
utmost importance for establishing an accurate and 
personalized treatment strategy.6
The aim of this study was to explore the long-term 
outcomes of CIS patients from the Barcelona incep-
tion cohort. For this objective, we selected patients 
with a follow-up longer than 10 years to (1) estimate 
the risks of MS and disability accumulation according 
to baseline T2 lesion number and to compare treated 
versus untreated patients and early treatment versus 
delayed treatment, and (2) study the prevalence and 
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baseline features of patients with an aggressive MS 
phenotype, defined as patients with an EDSS ⩾6.0 at 
10 years.
Patients and methods
Study data and inclusion criteria
This is a retrospective analysis based on a prospective 
and open CIS cohort initiated in 1995. The cohort 
includes patients younger than 50 years who presented 
with a CIS suggestive of MS within 3 months of our 
first assessment. At baseline, we recorded the demo-
graphics, CIS topography and disability according to 
the EDSS score. The EDSS score and the occurrence 
of relapses were evaluated every 3–6 months or annu-
ally depending on each patient’s characteristics. For 
the purpose of this analysis, the database was locked 
on 15 February 2016. For the main analysis of the 
study, we included patients with a CIS before 15 
February 2006 and with at least 10 years of follow-up. 
IgG oligoclonal bands (OB) were examined within 
the first 3 months of disease onset via agarose isoelec-
tric focusing combined with immunoblotting.7 OB 
were considered positive when at least two discrete 
bands were demonstrated in cerebrospinal fluid (CSF) 
only or when the CSF had at least two more bands 
than serum.
Since 1996, disease-modifying treatment (DMT) was 
offered to patients presenting with at least two attacks 
in the previous 3 years according to the Catalonian 
Regulatory Agency guidelines. After 2001, patients 
presenting with a high-risk CIS (defined as the fulfil-
ment of three to four Barkhof criteria) were also candi-
dates for treatment. Age and sex, date of the CIS, CIS 
topography, steroid treatment, date of the second attack, 
EDSS measurements, date of DMT initiation and date 
of the most recent visit were prospectively collected. 
The number and location of baseline T2 lesions, the 
presence and number of contrast-enhancing lesions 
(CEL) and the number of new T2 lesions were recorded 
during follow-up. For the purposes of this study, the 
number of T2 lesions at baseline was divided into four 
categories: 0, 1–3, 4–9 and 10 or more. In addition, a 
normal brain magnetic resonance imaging (MRI) was 
defined as displaying zero T2 lesions.
Finally, the patients’ clinical and MRI data were 
entered and updated on a regular basis. Quality con-
trols were performed including a review of the data 
using the primary sources of 10 randomly selected 
patients every month. This study received approval 
from the local ethics committee, and all patients 
signed a written informed consent form.
MRI protocol
The baseline brain MRI was performed 3–5 months 
after the CIS and repeated at 12 months and every 
5 years thereafter. Baseline spinal cord MRIs were 
systematically performed since 2007 and therefore 
were not considered in this study. Brain MRI was per-
formed using a 1.5 or 3.0 T magnet and included the 
following sequences: transverse proton density and 
T2-weighted conventional or fast spin-echo, trans-
verse and sagittal T2 FLAIR, and un-enhanced and 
contrast-enhanced (0.1–2.0 mmol/kg; scan delay, 
5–10 minutes) T1-weighted spin-echo. All sequences 
were obtained using a contiguous 3–5 mm slice thick-
ness covering the entire brain. Having a normal brain 
MRI was not an exclusion criterion, since patients 
were included based solely on their clinical features if 
they were suggestive of MS (i.e. patients with optic 
neuritis and normal baseline brain MRIs are included).
Definition of the outcomes
The 2017 McDonald criteria were applied to patients 
included after 2002 as lesion topography was not 
assessed individually before this date. For patients 
included from 1995 to 2002, the 2005 McDonald cri-
teria were used.8,9 Clinically definite multiple sclerosis 
(CDMS) was established when new symptoms sug-
gestive of a relapse occurred after an interval of at 
least 1 month.10 Disability was evaluated according to 
the EDSS at each visit during stability periods.11 The 
primary disability milestones were defined as reaching 
an EDSS score greater than or equal to 3.0 or 6.0 in 
two different evaluations. Finally, the follow-up dura-
tion was computed as the time elapsed between the 
date of the CIS and the date of the most recent visit.
Statistical analysis
Kaplan–Meier risk estimates were obtained for the 
times to McDonald MS, CDMS and EDSS score of 
3.0 and 6.0 according to the number of baseline T2 
lesions. Instead of representing the resulting estimates 
using curves, we used heat maps to represent the pro-
portion of patients achieving each of the four out-
comes during follow-up. In the heat maps, columns 
represent follow-up time in years and rows indicate 
the number of baseline lesions. Thus, each cell of the 
map shows the proportion of patients (with its 95% 
confidence interval) fulfilling each outcome for each 
time point according to the number of baseline lesions. 
Heat maps offer the possibility of using colours as a 
scoring gradient that goes from blue (low risk) to red 
(high risk). The same range of colours has been used 
in the four heat maps to allow for an easier compari-
son of risks between outcomes (Figure 2). These 
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estimates have been computed and represented until 
the last time point where an event or censoring hap-
pened. Thus, the heat map stops when the population 
under risk remained constant. Univariable and multi-
variable Cox proportional-hazards (PH) regressions 
were built for the progression to EDSS scores of 3.0 
and 6.0. Covariates including age, sex, CIS topogra-
phy, OB, baseline number of T2 lesions, MRI criteria 
and DMT status were considered. This last variable 
was first considered a time-dependent exposure and 
modelled later as an indicator of whether the DMT 
was initiated before or after the second attack. Possible 
interactions between age, sex, CIS topography, pres-
ence of OB, number of baseline T2 lesions and DMT 
were also evaluated (Figure 3). We defined the aggres-
sive MS phenotype as reaching an EDSS ⩾6.0 at 
10 years. We compared patients who presented this 
phenotype to those who did not in terms of sex, age at 
CIS, CIS topography, OB status, and number of T2 
lesions and CEL at baseline (Figure 4). Next, we cal-
culated the cut-off number of baseline T2 lesions and 
CEL that best predicted the development of an aggres-
sive MS (Figure 4(b)). Both cut-offs were defined as 
those with the best balance between sensitivity and 
specificity rates. Finally, we combined both MRI var-
iables to estimate the positive predictive values (PPV) 
of developing aggressive MS (Table 3).
A p-value of 0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS 22.0 




From January 1995 to 15 February 2016, 1207 
patients were enrolled in the prospective CIS cohort; 
70 (5.8%) were ultimately excluded for various rea-
sons: previous attack (n = 13), age above 50 (n = 4), 
exceeded entry window (n = 26) and alternative diag-
noses (n = 27). These alternative diagnoses included 
acute disseminated encephalomyelitis (n = 1), neuro-
myelitis optica spectrum disorder (n = 5), chronic 
relapsing inflammatory optic neuritis associated with 
anti-MOG antibodies (n = 1), brain tumour (n = 5), 
ischemic stroke (n = 2), cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CADASIL; n = 1), anterior ischemic 
optic neuropathy (n = 3), Leber’s hereditary optic neu-
ropathy (n = 1), central nervous system vasculitis 
(n = 1), atypical brainstem lesions (n = 2), alcoholic 
polyneuropathy with vitamin B deficiency (n = 1), 
musculoskeletal disorders (n = 2), unspecified sensory 
symptoms (n = 1) and unspecified ophthalmological 
condition (n = 1).
According to the database lock date, we identified 
562 cases with a CIS before 15 February 2006 and at 
least one follow-up visit (Figure 1). Of these, 401 
(71.3%) patients had a minimum follow-up of 10 years 
(Figure 1). Compared to these, patients with a shorter 
follow-up (n = 161, 28.6%) were similar in age but 
were more likely to have a normal baseline MRI and 
negative OB (Supplementary Table 1).
Ultimately, 401 patients were included in this analy-
sis. Of these, one died during follow-up due to an 
acute myeloid leukaemia with a complex karyotype 
not related to MS treatment.
Table 1 shows the baseline characteristics of this 
long-term cohort: as expected, two out of three were 
females, the mean age at onset was 30 years and one-
third presented with an optic neuritis. The mean clini-
cal follow-up duration was 14.4 (standard deviation 
(SD) 2.9) years. Of the total cohort, 334 patients 
underwent a CSF tap, of whom 221 (66.2%) had posi-
tive OB. The baseline brain MRI was normal in 20.5% 
of the patients, almost half of the patients displayed 
10 or more T2 lesions, and one-third showed at least 
one CEL. Out of the entire cohort, 190 (47.4%) 
patients received no DMT; 55 (13.7%) initiated a 
DMT prior to their second attack and 156 (38.9%) 
after their second attack.
The median time from CIS onset to drug prescription 
was 23.5 months (interquartile range (IQR): 8.3–63.2).
Long-term outcomes: CDMS, McDonald MS, and 
EDSS of 3.0 and 6.0
Figure 2 shows the proportion of patients reaching 
each of the four outcomes according to the number of 
baseline T2 lesions. A higher number of T2 lesions 
was associated with an earlier second attack and an 
earlier McDonald MS diagnosis. In addition, the risk 
of irreversible disability was especially worrisome in 
patients with at least 10 baseline lesions: 30% of them 
reached an EDSS of 3.0, and 7% needed a cane before 
10 years. These numbers rose to 39% and 9% within 
the first 15 years of the disease, respectively.
Long-term outcomes: treated versus not treated 
patients
Patients who were treated had clearly a more aggres-
sive phenotype (Supplementary Table 2). It is worth 
highlighting that covariates were not balanced across 
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treated and untreated groups. Thus, time-dependent 
variables could not control for this unbalance, and no 
further analyses comparing treated and untreated 
patients were performed.
Long-term outcomes in treated patients: DMT 
before or after the second attack
Table 2 compares the baseline characteristics of 
patients who received an early treatment (median 
time: 4 months) and patients starting treatment after 
the second attack (median time: 36 months). Although 
patients who received an early treatment had a higher 
number of T2 and CEL lesions at baseline, univaria-
ble and multivariable analyses showed that treatment 
before the second attack was associated with a 
decreased risk (adjusted hazard ratio (aHR) = 0.4 (0.2, 
0.7)) of reaching an EDSS score of 3.0 (Figure 3). 
When analysing EDSS of 6.0 as the outcome, the haz-
ards proportionality assumption was violated (p-value 
of 0.2 in the log-rank test), and therefore no further 
research on this outcome was performed.
Aggressive MS: EDSS of 6.0 at 10 years
We compared the baseline characteristics of patients 
who presented with this aggressive phenotype to 
Figure 1. Flowchart: patient’s disposition.
CIS: clinically isolated syndrome.
Table 1. Baseline characteristics of patients with at least 





Females: n (%) 287 (71.6)
Mean (SD) age in years 30.0 (8.1)
CIS topography: n (%)
 ON 142 (35.4)
 BS 112 (27.9)
 SC 110 (27.4)
 Other 37 (9.2)
+OB: n (%) 221/334 (66.2)
Baseline number of T2 lesions on brain and SC MRI: 
n (%)
 0 80/391 (20.5)
 1–3 67/391 (17.1)
 4–9 56/391 (14.3)
 ⩾10 188/391 (48.1)
CEL: n (%) 97/239 (40.6)
Median (IQR) time of 
follow-up in years
14.0 (11.9–16.7)
SD: standard deviation; CIS: clinically isolated syndrome; 
ON: optic neuritis; BS: brainstem; SC: spinal cord; OB: 
oligoclonal bands; MRI: magnetic resonance imaging, CEL: 
contrast-enhancing lesions; IQR: interquartile range.
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those who did not. There were no differences in sex 
(76.9% of aggressive MS vs 72.7% of non-aggres-
sive MS, p = 1) and age at CIS (mean (SD) of 27.3 
(5.5) vs 30.1 (8.2) years, p = 0.1). Positive OB were 
more common in patients with aggressive MS (90.0% 
vs 65.4%, p = 0.174), although these differences were 
not statistically significant. On the contrary, treat-
ment was clearly more frequent on the aggressive 
cohort (92.3% vs 50.9%, p = 0.003). In terms of the 
MRI characteristics, all patients with aggressive MS 
presented 10 or more T2 lesions at baseline (100.0% 
vs 45.9%, p = 0.02) and more frequently presented 
at least one CEL (92.3% vs 50.9%, p = 0.003). 
Furthermore, the median (IQR) number of baseline 
T2 lesions was 71 (28–95) compared to 7 (1–19), and 
the median number of CEL was 3 (1–24) compared 
to 0 (0–1) (p < 0.0001 for both tests) (Figure 4).
In addition, presenting at least 20 T2 lesions at base-
line was the cut-off that best discriminated patients 
with aggressive MS from those who did not present 
this phenotype, with a sensitivity of 0.85 and a speci-
ficity of 0.76. Performing the same analysis for base-
line CEL, the best cut-off was at least two lesions, 
with a sensitivity of 0.73 and a specificity of 0.79 
(Figure 4). Table 3 shows the PPVs for developing 
aggressive MS for several combinations of baseline 
T2 lesions and CEL. If MRI information was not con-
sidered, the risk of having aggressive MS for patients 
in our cohort was 4.7% (Table 3). For patients having 
Figure 2. Heat maps showing the proportion of patients reaching McDonald MS, CDMS, and EDSS of 3.0 and 6.0 
according to the number of baseline T2 lesions.
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more than 20 T2 lesions and more than 2 CEL, this 
probability increased to 19.0% (10.4%, 28.1%). The 
probability further increased to 40% for patients with 
more than 20 T2 lesions and more than 10 CEL 
(14.3%, 71.4%).
Discussion
Our study confirmed that when the baseline MRI is 
abnormal, a high proportion of patients with CIS pre-
sented a second attack in the long term. Moreover, 
almost all patients developed McDonald MS. The 
heat maps show that a higher number of lesions is 
associated with an earlier outcome. Less than 5% of 
our patients developed an aggressive MS (reaching an 
EDSS status of 6.0 at 10 years). It is worth highlight-
ing that in patients with an aggressive phenotype, 
baseline characteristics such as sex, age and OB were 
not helpful in identifying them as patients at risk. 
Nevertheless, a higher proportion of OB, a lower pro-
portion of optic neuritis and a higher proportion of 
spinal cord CIS were observed. Comparing patients 
with an aggressive phenotype to those with a more 
standard evolution, the former mainly differed in their 
baseline brain MRIs: the median number of baseline 
T2 lesion was 71 (28–95) compared to 7 (1–19), and 
the median for CEL was 3 (1–24) compared to 0 (0–1). 
The cut-offs that better classified patients with aggres-
sive MS were 20 for T2 lesions and 2 for CEL. It is 
important to note that both the number and activity of 
the lesions seem to contribute to better predict patients 
with an aggressive MS phenotype. Also, we would 
like to highlight that there is no consensus on the defi-
nition of aggressive MS, and specific guidelines for 
its treatment are also lacking.
A high proportion of our patients received DMT during 
their follow-up, but for the majority of them, there was 
Table 2. Baseline characteristics of patients according to early versus delayed treatment.
Baseline characteristics DMT after CDMS 
(n = 156)
DMT before 
CDMS (n = 55)
p-value
Females: n (%) 112 (71.8) 39 (70.9) 1
Mean (SD) age in years 28.3 (7.3) 29.1 (7.7) 0.553
CIS topography: n (%)
 ON 47 (30.1) 14 (25.5) 0.320
 BS 50 (32.1) 16 (29.1)  
 SC 47 (30.1) 16 (29.1)  
 Other 12 (7.7) 9 (16.4)  
+OB: n (%) 115/137 (83.9) 32/38 (84.2) 1.0
Baseline T2 brain lesions: n (%)
 0 2/154 (1.3) 0/52 (0) 0.053
 1–3 22/154 (14.3) 2/52 (3.9)  
 4–9 29/154 (18.8) 6/52 (11.5)  
 ⩾10 101/154 (65.6) 44/52 (84.6)  
CEL: n (%) 50/110 (45.4) 31/47 (66.0) 0.029
Median(IQR) time to start 
treatment in months
36 (16–72) 4 (1–6) <0.001
Median (IQR) time of 
follow-up in years
14.6 (12.8–16.8) 12.0 (11–12.9) <0.001
Outcomes DMT after CDMS 
(n = 156)
DMT before 
CDMS (n = 55)
p-value
CDMS 156 (100.0) 40 (72.7) < 0.001
2005 McDonald MS 156 (100.0) 43 (78.2) < 0.001
2017 McDonald MS 66/66 (100.0) 43/46 (93.5) 0.067
Confirmed EDSS of 3.0 74 (47.4) 11 (20.0) < 0.001
Confirmed EDSS of 6.0 11 (7.1) 4 (7.3) 1.0
DMT: disease-modifying treatment; CDMS: clinically definite multiple sclerosis; SD: standard deviation; CIS: clinically isolated 
syndrome; ON: optic nerve; BS: brainstem; SC: spinal cord; OB: oligoclonal bands; CEL: contrast-enhancing lesions; MS: multiple 
sclerosis; EDSS: Expanded Disability Status Scale. IQR: Interquartile range.
All tests are Fisher’s exact and chi-square tests, except for age (Student’s t-test) and follow-up time (Mann–Whitney test).
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a long time between the first clinical event and treat-
ment initiation. These data reflect our clinical practice 
two decades ago when the concept of early treatment 
was in its infancy. Treated patients had a more aggres-
sive disease phenotype than untreated patients, and for 
this reason we were unable to match both populations. 
In our study, after excluding non-treated patients, it 
appeared that treatment before the second attack could 
decrease the risk of disability accumulation, highlight-
ing the importance of early treatment. As a rule, patients 
were treated with first-line treatments. This study is in 
line with our previous work analysing our whole cohort 
of 1058 CIS patients followed up for a mean of 
6.5 years, in which we showed that MRI features (num-
ber and topography of T2 lesions) were the main prog-
nostic factor at disease onset and that initiation of a 
DMT before a second attack could reduce the risk of 
disability accumulation.12 Focusing on patients with 
more than 10 T2 lesions at baseline, compared to the 
London cohort, we found similar rates of patients pre-
senting a second attack (80% vs 85% at 10 years).13,14 
Although a small proportion of our patients started 
DMT before their second attack (n = 55), compared to 
the largely untreated London CIS cohort, these similar 
rates of conversion probably reflect the fact that first-
line DMTs (mainly interferons and glatiramer acetate 
in our cohort) only delay the occurrence of second 
attack in the short to medium term. Conversely, in 
patients with at least 10 baseline T2 lesions, we found 
lower rates of disability accumulation than the London 
cohort (30% vs 75% for EDSS of 3.0 and 7% vs 35% 
for EDSS of 6.0 at 10 years). Our rates of disability are 
closer to other treated cohorts: The Betaferon® / 
Betaseron® in Newly Emerging Multiple Sclerosis for 
Initial Treatment (BENEFIT) cohort reported 30% of 
patients with an EDSS of 3.0 and 6% with an EDSS of 
Figure 3. Multivariable Cox model results for reaching an EDSS of 3.0 in treated patients: initiation of DMT before or 
after CDMS.
EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; CDMS: clinically definite multiple sclerosis; OB: 
oligoclonal bands; HR: hazard ratio; CI: confidence interval.
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Figure 4. (Continued)
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Figure 4. Baseline MRI characteristics and cut-offs obtained at baseline for aggressive and non-aggressive MS.
IQR: interquartile range; SD: standard deviation; EDSS: Expanded Disability Status Scale, sens: sensibility, spec: specificity, acc: 
accuracy, PPV: positive predictive value, NPV: negative predictive value; LR+: positive likelihood ratio.
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6.0 after an 11-year follow-up.15 This is also in line 
with the expression/genomics, proteomics, imaging, 
and clinical (EPIC) cohort, a prospective single-centre 
cohort including actively managed CIS and early MS 
patients which showed 4.7% of patients reaching an 
EDSS of 6.0 after 10 years.16 Taking all together, and 
considering other important factors such as the Will 
Rogers phenomenon derived from diagnostic criteria 
modifications and improvement in general health 
among others, our data seem to confirm that natural 
history is changing in the treated era. Others have 
addressed the impact of first-line treatments on long-
term disability in relapsing MS patients.17,18 This pro-
tective effect is modest in patients treated with first-line 
drugs, with an estimated prevention of 1.0 EDSS point 
increase for every 11.6 years of interferon-beta/glati-
ramer acetate exposure.19
Limitations of our study include the following aspects: 
MRI criteria to define MS have changed overtime, and 
therefore not all patients had the required information 
to apply the 2017 McDonald criteria. To overcome this 
limitation, a combination of 2005 and 2017 criteria has 
been used. Another concern relates to the lack of spi-
nal cord imaging in this analysis. Unfortunately, this 
limitation reflects our practice at a time where spinal 
cord MRI was only performed in patients presenting 
with a myelitis. The treatments that were available at 
that time were mainly interferons and glatiramer 
acetate. The use of other treatments was restricted to 
exceptional cases. Again, only an intention-to-treat 
analysis has been performed taking into consideration 
the date of initiation of DMT. However, time on 
treatment or changes among preparations have not 
been evaluated. We also acknowledge that this is a cul-
turally and genetically homogeneous cohort, as non-
Caucasian people were an exception in our setting. We 
are also aware that the conclusions referring to patients 
with aggressive MS are based on a limited number of 
patients. This could have limited the possibility of 
finding statistically significant differences in other 
variables such as OB. However, this limitation also 
mirrors the exceptionality of this end point.
The data from the long-term Barcelona cohort confirm 
that patients with a normal baseline MRI have a low 
risk of developing MS after 10 or 15 years of follow-
up. Conversely, patients with an abnormal MRI have a 
very high risk of developing further attacks or 
McDonald MS. In line with other cohort studies, we 
showed that early treatment seems to prevent disability 
accrual. Our long-term study confirms that MS natural 
history has changed and that aggressive MS, defined as 
reaching an EDSS of 6.0 at 10 years, is infrequent in the 
treatment era. A high lesion load (more than 20 T2 
lesions and more than 2 CEL) at onset was helpful to 
identify patients at risk of an aggressive MS.20
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